Dr. Ignatz-hoover is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
11100 Euclid Ave
Cleveland, OH 44106Phone+1 216-844-1000
Education & Training
Case Western Reserve University School of MedicineClass of 2018
Certifications & Licensure
OH State Medical License 2018 - 2027
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Melphalan 140 mg/mis Safe and Effective for Frail and Older Multiple Myeloma Patients With Comparable Rates of Minimal Residual Disease Negativity.Jeries Kort, Nikolas Naleid, Frank Oley, James Ignatz-Hoover, Seunghee Margevicius
Clinical Lymphoma, Myeloma & Leukemia. 2025-02-20 - 1 citationsImmunoproteasome Activation Expands the MHC Class I Immunopeptidome, Unmasks Neoantigens, and Enhances T-cell Anti-Myeloma Activity.Priyanka S Rana, James J Ignatz-Hoover, Chunna Guo, Amber L Mosley, Ehsan Malek
Molecular Cancer Therapeutics. 2024-12-03 - 2 citationsThe TGFβ type I receptor kinase inhibitor vactosertib in combination with pomalidomide in relapsed/refractory multiple myeloma: a phase 1b trial.Ehsan Malek, Priyanka S Rana, Muthulekha Swamydas, Michael Daunov, Masaru Miyagi
Nature Communications. 2024-08-27
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
